Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

RESCUE OF HUMAN MONOCLONAL-ANTIBODY PRODUCTION FROM AN EBV-TRANSFORMED B-CELL LINE BY FUSION TO A HUMAN-MOUSE HYBRIDOMA JOURNAL OF IMMUNOLOGICAL METHODS Foung, S. K., Perkins, S., Raubitschek, A., LARRICK, J., LIZAK, G., Fishwild, D., Engleman, E. G., GRUMET, F. C. 1984; 70 (1): 83-90

Abstract

A human-mouse cell line that is hypoxanthine-aminopterin-thymidine sensitive and ouabain resistant was derived from a fusion between human B lymphocytes and a mouse myeloma line. This new mutant, when fused to a relatively unstable EBV-transformed B cell secreting a human monoclonal anti-A (red blood cell antigen) antibody, resulted in stable hybridomas capable of long term production of the specific human monoclonal antibody. Furthermore, some of the hybrid clones secreted antibody in far greater titer than the original EBV cell line. We conclude that fusion to this human-mouse line is an efficient approach to the production of human monoclonal alloantibodies and an effective method of 'rescuing' secretion of desired antibody from EBV cell lines.

View details for Web of Science ID A1984SR32200010

View details for PubMedID 6201562